High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

NCT06812871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: furmonertinib

Sponsor

Sun Yat-sen University